Mazama Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Mazama Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-13,507	Closed	-$834K	–	285
2014 Q4	$834K	Buy	13,507 +4,974	+58%	+$245K	0.19%	149
2014 Q3	$331K	Sell	8,533 -2,436	-22%	-$86.3K	0.08%	197
2014 Q2	$377K	Buy	+10,969	New	+$345K	0.1%	192
2014 Q1	–	Sell	-706	Closed	-$28K	–	271
2013 Q4	$28K	Buy	+706	New	+$25.2K	0.01%	206

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Mazama Capital Management's IONS Position: Q1 2015 in Review

Mazama Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2015, closing a stake of 13,507 shares — an estimated $834K sold.

Mazama Capital Management first reported a position in IONS in Q4 2013 and held it in 4 quarters. The position peaked at $834K in Q4 2014. 339 funds tracked by Wall St. Rank hold IONS as of Q1 2015.

Mazama Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Mazama Capital Management sold 13,507 Ionis Pharmaceuticals shares in Q1 2015, an estimated $834K.
Mazama Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2013 and held it in 4 quarters.
Mazama Capital Management's Ionis Pharmaceuticals position peaked at $834K in Q4 2014.
339 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2015.

Based on Mazama Capital Management's 13F filing for Q1 2015, filed 15 May 2015.